中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
29期
25-26,27
,共3页
米热尼沙·阿不都热西提%迪丽拜尔·达吾提
米熱尼沙·阿不都熱西提%迪麗拜爾·達吾提
미열니사·아불도열서제%적려배이·체오제
稳定期%慢性阻塞性肺疾病%舒利迭%疗效
穩定期%慢性阻塞性肺疾病%舒利迭%療效
은정기%만성조새성폐질병%서리질%료효
Stable%Chronic obstructive pulmonary disease%Seretide%Curative effect of seretide
目的:探讨慢性阻塞性肺疾病(COPD)稳定期采用吸入舒利迭治疗的临床疗效。方法:随机抽取本院收治的稳定期COPD患者68例,分成对照组33例和观察组35例,其中对照组均给予祛痰剂(如氨溴索胶囊)、茶碱缓释片进行常规口服治疗,观察组均在常规治疗的基础上加用舒利迭吸入配合治疗,两组疗程均为1年,对两组患者的临床疗效进行对比分析。结果:治疗1年后,观察组患者的呼吸困难程度明显好转,且临床症状评分下降显著,两组比较差异有统计学意义(P<0.05)。同时,治疗后观察组患者的FEV1(即第一秒用力呼气量)、FEV1/FVC(%)(即1秒用力呼气量占肺活量百分比)和FEV1占预计值百分比(%)增加较明显,差异有统计学意义(P<0.05)。而对照组治疗前后上述数据却无明显改变,差异无统计学意义(P>0.05)。结论:COPD稳定期患者采用吸入舒利迭治疗效果明显,且用药安全,值得临床推广。
目的:探討慢性阻塞性肺疾病(COPD)穩定期採用吸入舒利迭治療的臨床療效。方法:隨機抽取本院收治的穩定期COPD患者68例,分成對照組33例和觀察組35例,其中對照組均給予祛痰劑(如氨溴索膠囊)、茶堿緩釋片進行常規口服治療,觀察組均在常規治療的基礎上加用舒利迭吸入配閤治療,兩組療程均為1年,對兩組患者的臨床療效進行對比分析。結果:治療1年後,觀察組患者的呼吸睏難程度明顯好轉,且臨床癥狀評分下降顯著,兩組比較差異有統計學意義(P<0.05)。同時,治療後觀察組患者的FEV1(即第一秒用力呼氣量)、FEV1/FVC(%)(即1秒用力呼氣量佔肺活量百分比)和FEV1佔預計值百分比(%)增加較明顯,差異有統計學意義(P<0.05)。而對照組治療前後上述數據卻無明顯改變,差異無統計學意義(P>0.05)。結論:COPD穩定期患者採用吸入舒利迭治療效果明顯,且用藥安全,值得臨床推廣。
목적:탐토만성조새성폐질병(COPD)은정기채용흡입서리질치료적림상료효。방법:수궤추취본원수치적은정기COPD환자68례,분성대조조33례화관찰조35례,기중대조조균급여거담제(여안추색효낭)、다감완석편진행상규구복치료,관찰조균재상규치료적기출상가용서리질흡입배합치료,량조료정균위1년,대량조환자적림상료효진행대비분석。결과:치료1년후,관찰조환자적호흡곤난정도명현호전,차림상증상평분하강현저,량조비교차이유통계학의의(P<0.05)。동시,치료후관찰조환자적FEV1(즉제일초용력호기량)、FEV1/FVC(%)(즉1초용력호기량점폐활량백분비)화FEV1점예계치백분비(%)증가교명현,차이유통계학의의(P<0.05)。이대조조치료전후상술수거각무명현개변,차이무통계학의의(P>0.05)。결론:COPD은정기환자채용흡입서리질치료효과명현,차용약안전,치득림상추엄。
Objective:To investigate the clinical curative effect of seretide in treatment of chronic obstructive pulmonary disease(COPD)in stable phase.Method:68 patients who had be attacked by a disease of COPD in stable phase from our hospital were randomly selected and divided into control group(33 cases)and observation group(35 cases). The control group were given an expectorant such as the ambroxol hydrochloride capsules and theophylline sustained-release tablets for conventional oral treatment.The observation group patients added Seretide inhalation treatment on the basis of control group. The clinical efficacy of the two groups were compared after treatment for one year. Result:After one year treatment,the degree of dyspnea improved obviously and the clinical symptom score decreased significantly of the observation group(P<0.05).At the same time,FEV1( the forced expiratory volume in 1 second),FEV1/FVC(%)(forced expiratory volume in 1 second for FVC%)and FEV1 percentage of predicted value(%)of the patients in the observation group after treatment increased significantly(P<0.05),while the control group was no statistical significance(P>0.05). Conclusion:Inhaling Seretide is sure and safe in treatment of COPD patients in stable phase,worthy of clinical application.